Perpetua Medical (PERP) Q3 2025 earnings summary

Executive summary

• Achieved a financial breakthrough in Q3 2025, driven by the sale of legacy assets and the acquisition of Spirotronic AB.

• Strong growth in revenue and operating profit, reflecting successful business transformation and cost control.

Financial highlights

• Q3 2025 net revenue: 3,477 KSEK (up 803% year-over-year); 9,404 KSEK for Jan–Sep 2025 (up 239%).

• Q3 operating profit: 7,514 KSEK (vs. -1,166 KSEK last year); Jan–Sep operating profit: 5,172 KSEK (vs. -1,117 KSEK).

• Q3 EPS: 1.58 SEK (vs. -0.25 SEK); Jan–Sep EPS: 1.14 SEK (vs. -0.27 SEK).

• Cash at period end: 6,445 KSEK (vs. 8,771 KSEK last year).

• Q3 cash flow: 455 KSEK; Jan–Sep cash flow: -2,956 KSEK.

• Equity at period end: 16,055 KSEK; equity ratio: 34%.

Outlook and guidance

• Continued focus on acquiring profitable, product-oriented healthcare companies.

• Ongoing investment in Spirotronic to strengthen consulting and product offerings.

• Plans to expand ES-Medical’s product reach beyond Sweden into Europe.